Most cancers therapy co UroGen invests $7m in Israels IntraGel
Israeli-US drug growth firm UroGen Pharma (Nasdaq: URGN), which develops and markets therapy for urological cancers and is at the moment traded on Wall Road with a market cap of $2.4 billion, in the present day introduced a strategic collaboration settlement with Israeli injectables developer IntraGel Therapeutics.
UroGen will make investments $7 million in IntraGel together with $4 million instantly and one other $3 million in keeping with close by milestones, as a part of a financing spherical that the corporate is at the moment elevating. If the product succeeds in Section II trials, which can quickly start, UroGen will train an choice to proceed growth and market the therapy if it efficiently receives approval in alternate for extra milestone funds and royalties.
UroGen’s present merchandise are additionally based mostly on a gel that enables for the delayed launch of medication into the urinary system, however the benefit of InraGel’s product is that it may be injected and is biodegradable contained in the physique, in contrast with UroGen’s gel, which after releasing the drug is washed out by urine.
Due to this fact, UroGen’s gel is appropriate for tumors in open locations, such because the urinary tract and digestive system, whereas InraGel’s can also be appropriate for treating varied forms of strong tumors, and will enable UroGen to develop its market. TUroGen has reported income of about $100 million per 12 months from its first product, Jelmyto, and within the final quarter recorded income of $50 million from Zusduri, which was launched this 12 months. UroGen has about 250-300 workers, together with 45 Israel.
IntraGel cofounder and CEO Peter Siman stated, “UroGen’s management in localized oncology therapies and commercial-stage expertise make them a great collaborator to assist advance the SRGel platform and speed up the event of TumoCure. We see this collaboration as an essential validation of our SRGel platform and the scientific potential of our lead investigational product, TumoCure, whereas creating a robust pathway to speed up growth throughout a number of oncology indications.”
UroGen CEO Liz Barrett added, “This settlement characterize an essential step in increasing UroGen’s oncology pipeline and our technological capabilities. IntraGel’s biodegradable, sustained-release know-how enhances our experience in native drug supply whereas creating important optionality for future innovation. Past the chance to advance TumoCure, we consider the SRGel platform might probably allow a number of therapeutic approaches throughout a variety of strong tumors and supply a basis for brand spanking new product alternatives over time.”
Revealed by Globes, Israel enterprise information – en.globes.co.il – on August 20, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
